Scarica l'app Stockscreener
3.44
0.86%
-0.03
Dopo l'orario di chiusura:
3.49
0.05
+1.45%
Precedente Chiudi:
$3.47
Aprire:
$3.49
Volume 24 ore:
402.99K
Relative Volume:
1.79
Capitalizzazione di mercato:
$112.57M
Reddito:
$1.95M
Utile/perdita netta:
$-47.84M
Rapporto P/E:
-2.3193
EPS:
-1.4832
Flusso di cassa netto:
$-27.46M
1 W Prestazione:
-12.24%
1M Prestazione:
-14.21%
6M Prestazione:
-8.51%
1 anno Prestazione:
+2.99%
Intervallo 1D:
$3.36
$3.60
Intervallo di 1 settimana:
$3.07
$3.99
Portata 52W:
$2.42
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Nome
Insight Molecular Diagnostics Inc
Settore
Industria
Telefono
949-409-7600
Indirizzo
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, NTRA, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
3.44 | 128.28M | 1.95M | -47.84M | -27.46M | -1.4832 |
TMO
Thermo Fisher Scientific Inc
|
654.80 | 249.58B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
214.06 | 157.81B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
410.35 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.78 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
258.21 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Iniziato | Lake Street | Buy |
| 2022-05-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-03-17 | Ripresa | Needham | Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Iniziato | BTIG Research | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Reiterato | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Iniziato | Needham | Buy |
| 2019-02-13 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-29 | Aggiornamento | Janney | Neutral → Buy |
| 2018-12-19 | Ripresa | Lake Street | Buy |
Mostra tutto
Insight Molecular Diagnostics Inc Borsa (IMDX) Ultime notizie
Insight Molecular Diagnostics Revises Chronix Royalty Agreement Terms - TipRanks
Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026 - TradingView
Insight Molecular Diagnostics Inc. Share PriceIMDX, RNS News, Articles, Quotes, & Charts (NASDAQ:IMDX) - proactiveinvestors.com
Insight Molecular (IMDX) shifts Chronix earnout to CNI Monitor test - Stock Titan
Insight Molecular Diagnostics Inc.(NasdaqCM: IMDX) added to S&P Global BMI Index - marketscreener.com
Insight Molecular Diagnostics Inc (OCX) Stock Price Quote Today & Current Price Chart - Capital.com
Insight Molecular Diagnostics (IMDX) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Medicare policy boosts iMDx transplant testing frequency - scanx.trade
Insight Molecular Diagnostics Inc. (IMDX) Slips 1.94% to $4.04 as Key Support HoldsGamma Squeeze - dars.gov.et
iMDx executives are set to meet investors in New York - Stock Titan
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference - GlobeNewswire
IMDX Q2 2026 Earnings: Wider-than-Expected Loss Sends Shares Down 3.73%Earnings Per Share - careplusvn.com
Lucid Capital Markets initiates Insight Molecular stock with buy rating By Investing.com - Investing.com Nigeria
Insight (IMDX) Quarter in Focus: Profit Per Share Clears Its Benchmark on the Day; Shares Move 0.93% Higher on the DayWeak Earnings Momentum - dars.gov.et
Insight Molecular Diagnostics Earnings Call Balances Risk - TipRanks
Insight (IMDX) Price: Adds 2.34% to Close at $4.38 in Latest Trading; Price Levels: the $4.16 to $4.60 Range Remains in Focus in the Current UpdateTriangle Correction - vinanet.vn
Insight (IMDX) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Market Read: The Stock Gains 0.23% at the CloseEarnings Surprise Score - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
IMDX Reiterated by Needham -- Price Target Maintained at $9.00 - GuruFocus
Needham Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Insight Molecular Diagnostics advances heart tr... - Pluang
Insight Molecular Diagnostics Inc. (IMDX) - Zacks Investment Research
Insight Molecular Diagnostics (IMDX) Drops 6.4% to $4.21 as Sellers Target $4.00 SupportDescending Triangle - dars.gov.et
Rest-Of-Europe Molecular Cytogenetics Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Germany Molecular Cytogenetics Market Size, Share,Trends, Growth Analysis Report, 2030 - marketsandmarkets.com
Insight Molecular Diagnostics hosts virtual KOL event on GraftAssure platform - scanx.trade
OCX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Insight Molecular Diagnostics to Host Virtual KOL Event on - GlobeNewswire
Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
IMDX Looks 284.7% Overvalued on GF Value™ - GuruFocus
Insight Molecular Diagnostics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Insight Molecular Nears FDA Authorization for GraftAssureDx Assay - TipRanks
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Insight Molecular Q2 EPS beats as FDA review advances - scanx.trade
Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results - Investing.com Nigeria
Insight Molecular Diagnostics earnings beat, revenue fell short of estimates - Investing.com
Form 8K Insight Molecular Diagnostics Inc For: 10 August By Investing.com - Investing.com South Africa
Insight Molecular Diagnostics: Q2 Earnings Snapshot - marketscreener.com
IMDX: FDA review progresses, Medicare expands coverage, and Q2 loss narrows on cost discipline - TradingView
Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash - Stock Titan
Insight Molecular Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx - The Manila Times
IMDX Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers 55% EPS SurpriseEPS Surprise History - dars.gov.et
Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
IMDX Looks 289.5% Overvalued on GF Value™ - GuruFocus
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Insight Molecular Diagnostics (IMDX) Slides 3.6% to $4.82: Support Test in FocusMedian Line - careplusvn.com
IMDX Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView
Insight Molecular Diagnostics Inc Azioni (IMDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insight Molecular Diagnostics Inc Azioni (IMDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 27 '26 |
Buy |
3.64 |
250,923 |
913,134 |
12,684,884 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 24 '26 |
Buy |
3.53 |
38,880 |
137,083 |
12,433,961 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 16 '26 |
Buy |
3.45 |
102,057 |
351,658 |
12,033,896 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 20 '26 |
Buy |
3.88 |
40,690 |
157,967 |
12,114,700 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Apr 17 '26 |
Buy |
3.57 |
40,114 |
143,251 |
12,074,010 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Feb 10 '26 |
Buy |
5.75 |
521,739 |
2,999,999 |
11,931,839 |
| James Andrea S. | Chief Financial Officer |
Oct 31 '25 |
Option Exercise |
0.00 |
50,000 |
0 |
201,231 |
0.97%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):